How are energy investors positioned?
Investing.com - Oppenheimer initiated coverage on Pulse Biosciences (NASDAQ:PLSE) with an Outperform rating and a $22.00 price target, representing a 12-18 month outlook for the stock. The company, currently valued at $1.03 billion, trades at $15.30, with InvestingPro data showing strong liquidity metrics including a current ratio of 15.58.
The research firm cited Pulse Biosciences’ development of nanosecond pulsed field ablation (nsPFA) technology, a variant of pulsed field ablation that utilizes nanosecond pulse durations and high electric fields ranging from 10 to 80 kilovolts.
According to Oppenheimer, the technology’s hypothesized mechanism of action involves intracellular organelle injury-induced apoptosis, with preliminary evidence suggesting improved safety and efficacy compared to traditional microsecond PFA and radiofrequency ablation (RFA) in applications including thyroid ablation and atrial fibrillation treatments.
While acknowledging that pivotal trials are still needed to validate these benefits, Oppenheimer noted that Pulse Biosciences has "multiple shots on goal" with its technology platform and that "the science makes sense" behind the company’s approach.
The firm also expressed confidence in the company’s leadership, stating that an experienced CEO helps mitigate execution risk, contributing to their constructive outlook on the stock. For deeper insights into PLSE’s valuation and growth prospects, investors can access comprehensive analysis through InvestingPro’s detailed research reports.
In other recent news, Pulse Biosciences reported a net loss of $16.8 million for the first quarter of 2025. This financial result reflects increased expenses as the company continues to invest heavily in developing its nanosecond pulse field ablation (NSPFA) technology. Despite the losses, the company raised $14 million through warrant exercises, maintaining a strong cash position of $119.3 million. Pulse Biosciences anticipates generating revenue in the latter half of 2025 as it expands its clinical trials and product offerings. The company is focusing on its NSPFA technology, aiming to disrupt the market for thyroid nodule treatments and atrial fibrillation with less invasive solutions. Analysts from various firms have not yet issued upgrades or downgrades following this report. The company’s strategic focus remains on innovation and expansion, with plans to begin IDE pivotal clinical trials mid-year. Pulse Biosciences is optimistic about its future revenue generation, backed by its ongoing clinical advancements and strategic expansion plans.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.